Pharmaceutical composition for treating lung cancer and application thereof

Abstract

The application discloses a pharmaceutical composition for treating lung cancer. The pharmaceutical composition comprises the following raw materials: radix angelicae sinensis, radix paeoniae rubra, radix ginseng, radix astragali, semen persicae, oyster, radix scrophulariae, semen vaccariae, radix curcumae, tabani, corydalis tuber, fructus amomi, radix angelicae, fructus schisandrae chinensis, herba epimedii, herba hedyotidis diffusae, spica prunellae, peimine, rhizoma smilacis glabrae, herba houttuyniae, and radix actinidiae chinensis. The invention has beneficial effects that: the pharmaceutical composition can remarkably inhibit proliferation of lung cancer cells, down-regulate expression of feroptosis key gene GPX4 in the lung cancer cells, promote content of lipid ROS in the lung cancer cells to be obviously increased, and promote feroptosis of the lung cancer cells. The invention provides new ideas for clinical lung cancer drug development. The pharmaceutical composition has long-lasting medicinal effect, easy absorption, small toxic and side effects, and reduced volume after concentration. In addition, raw material materials such as honey and the like are added to overcome defects of poor taste, inconvenient carrying and the like of other traditional Chinese medicine preparations.

Description

technical field [0001] The application relates to the technical field of traditional Chinese medicine, in particular to a pharmaceutical composition for treating lung cancer and its application. Background technique [0002] Lung cancer (LC) is the leading cause of cancer death worldwide. The morbidity and mortality of male patients rank first among all malignant tumors, and female patients also occupy the second place. This makes lung cancer the first among all kinds of tumors in terms of morbidity and mortality. Although the survival rate of most cancer patients has steadily improved with advances in diagnostic and treatment procedures, the mortality rate of lung cancer patients remains high, with a 5-year survival rate of only 17.7%, and lung cancer treatment still lacks powerful therapeutic drugs. [0003] Traditional Chinese medicine believes that lung cancer is mostly caused by internal deficiency of righteous qi and external invasion of evil poison. Hemoptysis, ches...

AI Technical Summary

Problems solved by technology

At present, surgical treatment of early lung cancer is a reliable means to obtain cure and long-term efficacy, but the efficacy is still not satisfactory

Radiotherapy and chemotherapy are effective for some patients in the short term, but they have severe side effects and a high rate of recurrence and metastasis, and most of them have only palliative effects

Images